UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair
UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair
Read moreFri, 06th Mar 2020 10:07
UK EXECUTIVE CHANGE SUMMARY: Abcam Board Confirms Support For Chair
Read moreUK TRADING UPDATE SUMMARY: Kromek To Make 2,000 Ventilators For UK
Read moreDiurnal Gets European Marketing Authorisation For Chronocort
Read moreUPDATE: Diurnal Placing Raises GBP11 Million For Drug Development
Read moreDiurnal Announces GBP7 Million Placing To Fund Drug Development
Read moreDiurnal Group Names Director Sam Williams Interim Chair
Read moreDiurnal Says US FDA Accepts New Drug Application For Alkindi Sprinkle
Read more(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Thursday that its new drug application (NDA) for 'Alkindi', or hydrocortisone granules in capsules for opening and to be known in the US as 'Alkindi Sprinkle', has been accepted for review by the US Food and Drug Administration (FDA).
Read more(Sharecast News) - Speciality pharmaceutical company Diurnal Group narrowed its first-half loss by 53% to ?4.6m, it announced on Tuesday, which it said reflected improved revenues and a reduction in clinical development expenses for the period.
Read moreDiurnal Loss Narrows In First Half Amid Improved Sales Of Alkindi
Read moreUK Earnings, Trading Statements Calendar - Next 7 Days
Read moreDiurnal In Good Health Ahead Of Second Half Amid Alkindi Progress
Read moreDiurnal Submits Market Authorisation Application For Chronocort
Read moreDiurnal Submits New Drug Application For Aklindi Sprinkle In US
Read more